Amicus Therapeutics, Inc. (AM6.F)
- Previous Close
9.85 - Open
9.55 - Bid 9.80 x 50000
- Ask 9.90 x 50000
- Day's Range
9.55 - 9.55 - 52 Week Range
9.25 - 13.20 - Volume
500 - Avg. Volume
16 - Market Cap (intraday)
2.821B - Beta (5Y Monthly) 0.76
- PE Ratio (TTM)
-- - EPS (TTM)
-0.48 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.90
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
amicusrx.comRecent News: AM6.F
Performance Overview: AM6.F
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AM6.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AM6.F
Valuation Measures
Market Cap
2.86B
Enterprise Value
3.01B
Trailing P/E
--
Forward P/E
71.94
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.77
Price/Book (mrq)
19.38
Enterprise Value/Revenue
7.54
Enterprise Value/EBITDA
-32.71
Financial Highlights
Profitability and Income Statement
Profit Margin
-37.96%
Return on Assets (ttm)
-6.12%
Return on Equity (ttm)
-107.04%
Revenue (ttm)
399.36M
Net Income Avi to Common (ttm)
-151.58M
Diluted EPS (ttm)
-0.48
Balance Sheet and Cash Flow
Total Cash (mrq)
286.2M
Total Debt/Equity (mrq)
277.86%
Levered Free Cash Flow (ttm)
-25.89M